Continue PPI Therapy

Phase 3

UUniversity of Nottingham

Continue PPI Therapy is one of 8 therapeutic programs targeting Ulcerative Colitis (UC). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ulcerative Colitis (UC)Recruiting

Ulcerative Colitis (UC)Phase 3

Recruiting

Competition

Competitive Landscape

10 competitors in Ulcerative Colitis (UC)

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Approved

2 2

Omvoh

Eli Lilly

Approved

1 3

Vancocin

HHikma Pharmaceuticals LLC

Phase 2

1 4

Ponvory

VVanda Pharmaceuticals

Phase 3

1 5

Continue PPI Therapy

UUniversity of Nottingham

Phase 3

1 6

AC-101

AAccro Bioscience (Suzhou) Limited

Phase 2

1 7

Alinia

RRomark Laboratories L.C.

Preclinical

1 8

Alpha-0261

AAlphaMol Science Ltd. (Shanghai)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

ApprovedRecruiting

Ulcerative Colitis (UC)

NCT07691138

Clinical

Trials by Indication[1]

Ulcerative Colitis (UC)1 trial

STOpping PPI Therapy in Inactive IBD Study (STOP-IT): A Feasibility Study

Recruiting·UUniversity of Nottingham·Approved·NCT07691138·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Continue PPI Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Continue PPI Therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Nottingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversity of Nottingham

Continue PPI Therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Ulcerative Colitis (UC)1 trial

References

Drug Info

Quick Facts

Related News